Bagneux (France) – Genomic Vision (FR0011799907 – GV, PEA-PME eligible), a biotechnology company that develops tools and services dedicated to the analysis and control of genome modifications (the “Company”), announces today today the issue of the first tranche of bonds convertible into shares with stock warrants (OCABSA) for a net amount of 1.920 million euros.
It is reminded that in the context of a press release dated May 20, 2022, the Company had announced the signing of an issuance contract on April 11, 2022 as amended on May 18, 2022 with Winance with a view to establishment of a financing line by issuing convertible bonds (the “CB”) into ordinary shares to each of which will be attached a share subscription warrant (the “BSA” and together with the shares to which they are attached the “ABSAs” and with the CBs the “OCABSAs”), for a total maximum net amount of €28.8 million (€30 million nominal value). The extraordinary general meeting of shareholders of the Company which met on May 23, 2022 approved the implementation of this financing.